The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 10, 2015

Filed:

Mar. 12, 2014
Applicant:

Anavex Life Sciences Corp., New York, NY (US);

Inventor:

Alexandre Vamvakides, Ymittos Attiki, GR;

Assignee:

Anavex Life Sciences Corp., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/495 (2006.01); A61K 31/4453 (2006.01); A61K 31/137 (2006.01); A61K 31/365 (2006.01); A61K 31/13 (2006.01); A61K 31/341 (2006.01); A61K 31/343 (2006.01); A61K 31/431 (2006.01); A61K 31/44 (2006.01); A61K 31/445 (2006.01); A61K 31/5377 (2006.01); A61K 31/5415 (2006.01); A61K 31/64 (2006.01); A61K 31/4525 (2006.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 31/13 (2013.01); A61K 31/341 (2013.01); A61K 31/343 (2013.01); A61K 31/365 (2013.01); A61K 31/431 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/4453 (2013.01); A61K 31/4525 (2013.01); A61K 31/495 (2013.01); A61K 31/5377 (2013.01); A61K 31/5415 (2013.01); A61K 31/64 (2013.01);
Abstract

The present invention involves new and original sigma receptors ligands: (Mono- or dialkylaminoalkyl)-γ-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl)benzene alkylamines, the N,N Dialkyl α-[(adamantyl-1)benzyloxy-2]alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.


Find Patent Forward Citations

Loading…